AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) An isolated, purified or synthetic compound selected from the group consisting of p~~P~~omolic acid, ~~its~~ isomers of pomolic acid and derivatives thereof, wherein the compound is effective to treat~~characterized by their use in the treatment of~~ multidrug resistant tumours. ~~, with the structure (I):~~

~~(I)~~

[[

]]

2. (Currently Amended) A p~~P~~harmaceutical composition for ~~the treatment of~~treating multidrug resistant ~~tumour~~tumors, said composition comprising an effective amount of at least one compound of~~characterized by the fact of containing a sufficient amount of pomolic acid, its isomers or derivatives in accordance with~~ claim 1 and at least one pharmaceutically acceptable vehicle~~pharmaceutical accepted vehicles~~.

3. (Currently Amended) The p~~P~~harmaceutical composition~~,~~ in accordance with claim 2, ~~characterized by the fact that~~wherein the at least one pharmaceutically acceptable vehicle ~~should be~~is acceptable for systemic or oral administration.

4. (Currently Amended) The p~~P~~harmaceutical composition~~,~~ in accordance with claim 2, ~~characterized by the fact that~~wherein the at least one pharmaceutically acceptable ~~accepted~~ vehicle is an organic solvent, further diluted in a saline solution or another equivalent isotonic solution.

5. (Currently Amended) The p~~P~~harmaceutical composition~~,~~ in accordance with claim 4, ~~characterized by the fact of~~wherein the organic solvent ~~be~~ is dimethylsulfoxide or another organic solvent acceptable to be used in humans, diluted in a saline solution.

6. (Currently Amended) The p~~P~~harmaceutical composition~~,~~ in accordance with claim 2, ~~characterized by the~~wherein a concentration of the compound~~pomolic acid, its isomers and/or derivatives, being utilized between~~ is from 0.1% ~~and~~ to 100% in weight/volume.

7. (Currently Amended) The p~~P~~harmaceutical composition~~,~~ in accordance with claim 6, ~~characterized by the fact that~~wherein the concentration ~~of pomolic acid, its isomers and/or derivatives, being utilized~~ is 10mg/ml to 1000 mg/ml.

8. (Currently Amended) A m~~M~~ethod to prepare ~~the~~ a pharmaceutical composition for ~~the treatment of~~treating multidrug resistant tumors, said method comprising solubilizing at least one compound selected from the group consisting of~~characterized by having a first step for the solubilization of~~ pomolic acid, ~~its~~ isomers of pomolic acid and/~~or~~ derivatives thereof, in ~~dimethylsulfoxide or another~~a pharmaceutically acceptable solvent for human use, followed by dilution in saline solution, in such a way that ~~the~~ a concentration of ~~dimethylsulfoxide~~ the pharmaceutically acceptable solvent does not exceed 1%.

9. (Currently Amended) The m~~M~~ethod to prepare the pharmaceutical composition~~,~~ in accordance with claim 8, ~~characterized by the fact that the~~wherein a concentration of the at least one compound is~~pomolic acid, its isomers and/or derivatives utilized in the first step of solubilization being~~ 10mg/ml to 1000 mg/ml.

10. (Currently Amended) A m~~M~~ethod for ~~the~~ treatment of multidrug resistance ~~tumour~~tumors ~~characterized by the~~comprising administration of a therapeutically efficacious amount of at least one compound selected from the group consisting of pomolic acid, ~~its~~ isomers of pomolic acid and~~/or~~ derivatives thereof.

11. (Currently Amended) The m~~M~~ethod for treatment~~,~~ in accordance with claim 10, ~~characterized by~~wherein the administration ~~of a therapeutically efficacious amount of pomolic acid, its isomers and/or derivatives~~ is systemic or oral.

12. (Currently Amended) The m~~M~~ethod for treatment~~,~~ in accordance with claim 11, ~~characterized by~~wherein the therapeutically efficacious amount ~~of pomolic acid, its isomers and/or derivatives, being between~~is from 0.01mg/kg ~~and~~ to 100mg/kg body weight.

13. (Canceled).

14. (Canceled).